Abel Hall LLC
CCCC icon

Abel Hall LLC’s C4 Therapeutics CCCC Stock Holding History

Abel Hall LLC’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$35.4K Buy
10,639
+406
+4% +$1.51K 0.01% 854
2026
Q2 		$47.8K Buy
10,233
+145
+1% +$496 0.01% 898
2026
Q1 		$26.5K Sell
10,088
-52
-0.5% -$122 0.01% 781
2025
Q4 		$19.4K Hold
10,140
– – ﹤0.01% 702
2025
Q3 		$22.5K Sell
10,140
-85
-0.8% -$204 0.01% 314
2025
Q2 		$14.6K Buy
+10,225
New +$14.9K 0.01% 274

Other funds holding CCCC

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Crestwood Advisors Group
Crestwood Advisors Group Boston, Massachusetts $6.76B AUM 24% 1-Year Est. Return
CV Advisors
CV Advisors Aventura, Florida $594M AUM 18% 1-Year Est. Return
Achmea Investment Management
Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
NBC Securities
NBC Securities Birmingham, Alabama $1.47B AUM 20.38% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Simplicity Wealth
Simplicity Wealth Summit, New Jersey $3.43B AUM 16.22% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Abel Hall LLC's CCCC Position: Q3 2026 in Review

Abel Hall LLC increased its C4 Therapeutics (CCCC) stake by 4% in Q3 2026, buying an estimated $1.51K and bringing the position to 10,639 shares worth $35.4K. The position accounts for 0.01% of the portfolio, ranked #854.

Abel Hall LLC first reported a position in CCCC in Q2 2025 and has held it in 6 quarters since. The position peaked at $47.8K in Q2 2026. 20 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Abel Hall LLC held 10,639 shares of C4 Therapeutics worth $35.4K as of Q3 2026.
  • Abel Hall LLC bought 406 C4 Therapeutics shares in Q3 2026, an estimated $1.51K.
  • C4 Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q3 2026, its #854 holding.
  • Abel Hall LLC first reported a position in C4 Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Abel Hall LLC's C4 Therapeutics position peaked at $47.8K in Q2 2026.
  • 20 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.